UNSPSC 51182109: Desmopressin acetate anhydrous

This classification denotes an antidiurectic hormone analogue with the molecular formula C46H64N14O12S2.C2H4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1K12647SFC, chemically known as 1-(3-mercaptopropionic acid)-8-d-arginine-vasopressin monoacetate (salt), but more generally known as desmopressin acetate anhydrous, which bears US NIH Compound Identifier 64758.

European Medicines Agency schedules desmopressin acetate anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07001MIG. Most nations, for tariff purposes, schedule desmopressin acetate anhydrous under HS 29371900. SMILES: CC(=O)O.C1CCC(CC1)C[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@H](C(=O)N2)CC3CCC(CC3)O)C(=O)N4CCC[C@H]4C(=O)N[C@H](CCCNC(=N)N)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N.

UNSPSC 51182109 Desmopressin acetate anhydrous is a Commodity code covering a specific pharmaceutical active ingredient supplied through state and local cooperative purchasing agreements for distribution across government healthcare facilities. State and local governments procure desmopressin acetate anhydrous as part of broader generic pharmaceutical contracts administered through multistate cooperative purchasing vehicles. The solicitations under this code reflect demand from state health departments, corrections systems, mental health facilities, and other state and local agencies operating healthcare programs. Vendors must hold current Good Manufacturing Practices (cGMP) certification and Drug Supply Chain Security Act (DSCSA) compliance, maintain relationships with established pharmaceutical wholesalers, and meet FDA labeling and shelf-life requirements.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 on January 20, 2026, establishing multiple-award contracts for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026. The RFP covers participating state and local government facilities in Minnesota and Oregon, with awarded vendors required to supply through three authorized wholesalers: AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC. Vendors must submit detailed product information including National Drug Codes (NDC), SKUs, and packaging configurations; pricing is weighted at 75 percent in evaluation, with compliance with administrative-fee format requirements and EDI capability each at 5 percent. Contract awards become effective July 1, 2026, with a two-year initial term and optional extensions at MMCAP's discretion through June 30, 2028 for incumbent responders. Vendors must carry $5,000,000 in commercial general liability insurance and pay a 3 percent administrative fee on all contract purchases.